Infliximab (Remicade, Inflectra, Renflexis)

Infliximab (Remicade, Inflectra, Renflexis) is covered for specified FDA‑approved non‑oncology indications and a defined list of off‑label compendial uses (e.g., Crohn’s, ulcerative colitis, RA, PsA, AS, plaque psoriasis, uveitis, Behçet’s, GVHD, hidradenitis suppurativa, JIA, etc.), while oncology uses and non‑listed off‑label indications are excluded. Coverage requires indication‑specific documentation (diagnosis, prior therapy trials/durations and responses, objective inflammation evidence when specified), adherence to age, weight‑based dosing and IV infusion (≥2 hours) limits, prescriber specialty or documented consultation as required, and demonstration of response for reauthorization, with defined initial and renewal approval durations.

"Approved Non-Oncology Off-Label Compendial Uses: Colitis, indeterminate."

Sign up to see full coverage criteria, indications, and limitations.